Audentes Therapeutics (BOLD) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
August 7, 2018 6:00 AM EDT-Â Â Â Â Â Â Â Â Â Muscle biopsy data demonstrate highly efficient tissue transduction as indicated by vector copy number, robust myotubularin protein expression as assessed by western blot, and significant improvement in histology in first three treated patients at 24-week timepoint
-Â Â Â Â Â Â Â Â Â Efficacy analysis updated to include week 24 assessments for Patient 3, demonstrating significant improvements in neuromuscular and respiratory function and reduction in ventilator dependence
-Â Â Â Â Â Â Â Â Â No serious adverse events in any patient since the last data update provided at ASGCT in May 2018
-Â Â Â Â Â Â Â Â Â Proceeding with per protocol dose escalation from 1x1014 vector genomes per kilogram (vg/kg) to 3x1014... More
